Department of Public Health Sciences, Queen's University, 62 Fifth Field Company Lane, Kingston, Ontario K7L 3N6, Canada; KFL&A Public Health, 221 Portsmouth Avenue, Kingston, Ontario K7M 1V5, Canada.
Department of Public Health Sciences, Queen's University, 62 Fifth Field Company Lane, Kingston, Ontario K7L 3N6, Canada.
Drug Alcohol Depend. 2021 Apr 1;221:108601. doi: 10.1016/j.drugalcdep.2021.108601. Epub 2021 Feb 13.
Long-term prescription opioid use has been associated with adverse health outcomes, including opioid use disorder (OUD). We examined a population of opioid naïve individuals who initiated prescription opioids for non-cancer pain and investigated the associations between opioid prescription characteristics at initiation and time to treated OUD.
We conducted a retrospective population-based cohort study in Ontario, Canada among opioid naïve individuals aged 15 years and older dispensed an opioid for non-cancer pain between 2013 and 2016. We used the Narcotic Monitoring System to abstract opioid dispensing data. A multivariable Cox regression model was used to examine the association between average daily dose and time to treated OUD.
We identified 1,607,659 opioid-naïve individuals who initiated a prescription opioid within the study period. The incidence of treated OUD within the study period was 86 cases per 100,000 person-years. Compared to an average daily dose of <20 morphine milligrams equivalent (MME), higher average daily doses at initiation were associated with greater hazard of treated OUD, 20-50 MME (HR 1.11, 95% CI: 1.02, 1.21), >50-90 MME (HR 1.29, 95% CI: 1.16, 1.44), >90-150 MME (HR 1.29, 95% CI: 1.06, 1.56), >150-200 MME (HR 2.49, 95% CI: 1.54, 4.03) and >200 MME (HR 4.15, 95% CI: 2.89, 5.97). Long-acting formulations and days' supply ≥11 days were also associated with greater hazard of treated OUD.
Prescription opioid characteristics at initiation are associated with risk of treated OUD, identifying potentially important and modifiable risk factors among people initiating opioids for non-cancer pain.
长期使用处方类阿片与不良健康后果相关,包括阿片类药物使用障碍(OUD)。我们研究了一组初始使用处方类阿片治疗非癌性疼痛的阿片类药物初治人群,并调查了起始时阿片类药物处方特征与治疗性 OUD 发病时间之间的关联。
我们在加拿大安大略省进行了一项回顾性基于人群的队列研究,研究对象为 2013 年至 2016 年间因非癌性疼痛而开具阿片类药物的年龄在 15 岁及以上的阿片类药物初治人群。我们使用麻醉品监测系统提取阿片类药物的配药数据。采用多变量 Cox 回归模型来检验平均日剂量与治疗性 OUD 发病时间之间的关系。
我们确定了 1607659 名在研究期间初始使用处方类阿片类药物的阿片类药物初治个体。在研究期间,治疗性 OUD 的发病率为每 100000 人年 86 例。与起始时平均日剂量<20 吗啡毫克当量(MME)相比,较高的平均日剂量与治疗性 OUD 的发病风险增加相关,20-50 MME(HR 1.11,95%CI:1.02,1.21),>50-90 MME(HR 1.29,95%CI:1.16,1.44),>90-150 MME(HR 1.29,95%CI:1.06,1.56),>150-200 MME(HR 2.49,95%CI:1.54,4.03)和>200 MME(HR 4.15,95%CI:2.89,5.97)。长效制剂和供应天数≥11 天也与治疗性 OUD 的发病风险增加相关。
起始时的处方类阿片类药物特征与治疗性 OUD 的风险相关,这为非癌性疼痛开始使用阿片类药物的人群确定了潜在重要和可改变的风险因素。